Role of Erlotinib in Influencing the Quality of Life of Cancer Patients

Deepika       Purohit; Parijat       Pandey

doi:10.2174/2212697X07999200820162006

Abstract

Background: Cancer is one of the significant causes of morbidity and mortality in patients globally. Lung cancer, among other cancers, remains to be one of the principal causes of deaths in both men and women. The most common type of lung cancer is non-small-cell lung cancer (NSCLC). Apart from lung cancer, pancreatic cancer is also currently one of the common cancers.

Objective: The assessment of QoL in erlotinib-treated patients can also prove to be very useful in the establishment of this drug as the main treatment option for patients with pancreatic and lung cancer.

Methods: Therapies that target EGFR-mediated signaling are the latest keystones for treating these two types of cancers. They comprise of two main treatment modalities: firstly, against the extracellular fields that include monoclonal antibodies, and secondly, mechanisms that create interferences in the signaling pathways, primarily the small molecule tyrosine kinase inhibitors.

Results: Quality of life (QoL) is one of the key advantages of erlotinib therapy over chemotherapy.

Conclusion: The present review reports the role of Erlotinib in improving the quality of life of cancer patients, especially in NSCLC and pancreatic cancers. The studies or trials establishing the relations between Erlotinib and QoL are discussed in detail in this review.

Keywords: Erlotinib, Quality of life, Lung cancer, Pancreatic cancer, Epidermal growth factor receptor, Patient compliance.

Graphical Abstract

[1] 
Sutcliffe SB. Cancer control: life and death in an unequal world. Curr Oncol  2012; 19(1): 12-5.
[http://dx.doi.org/10.3747/co.19.994] [PMID: 22328836] 
[2] 
Sudhakar A. History of cancer, ancient and modern treatment methods. J Cancer Sci Ther  2009; 1(2): 1-4.
[http://dx.doi.org/10.4172/1948-5956.100000e2] [PMID: 20740081] 
[3] 
Cancer Facts and Figures Atlanta: American Cancer Society 2019.  Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
[4] 
Soni N, Tekade M, Kesharwani P, et al. Advances in oncological submissions of dendrimer. Curr Pharm Des  2017; 23(21): 3084-98.
[http://dx.doi.org/10.2174/1381612823666170329150201] [PMID: 28356042] 
[5] 
Roser M, Ritchie H. Our world in data.  Available from: https://ourworldindata.org/grapher/share-of-population-suffering-from-cancer-types
[6] 
Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol  2013; 8(2): 229-37.
[http://dx.doi.org/10.1097/JTO.0b013e3182773fce] [PMID: 23328549] 
[7] 
Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol  2013; 24(6): 1615-22.
[http://dx.doi.org/10.1093/annonc/mdt012] [PMID: 23456778] 
[8] 
Cancer Facts and Figures Atlanta: American Cancer Society 2016.  Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf
[9] 
Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer  2003; 10(1): 1-21.
[http://dx.doi.org/10.1677/erc.0.0100001] [PMID: 12653668] 
[10] 
Pradhan R, Singhvi G, Dubey SK, Gupta G, Dua K. MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma. Future Med Chem  2019; 11(8): 793-5.
[http://dx.doi.org/10.4155/fmc-2018-0468] [PMID: 30994024] 
[11] 
Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist  2007; 12(7): 840-9.
[http://dx.doi.org/10.1634/theoncologist.12-7-840] [PMID: 17673615] 
[12] 
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol  2007; 18(3): 581-92.
[http://dx.doi.org/10.1093/annonc/mdl498] [PMID: 17287242] 
[13] 
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin  2012; 62(1): 10-29.
[http://dx.doi.org/10.3322/caac.20138] [PMID: 22237781] 
[14] 
International Agency for Research on Cancer (IARC). GLOBOCAN 2012: Estimated incidence, mortality and prevalence worldwide in 2012.  Available from: http://globocan.iarc.fr/Pages/fact
[15] 
Hidalgo M. Pancreatic cancer. N Engl J Med  2010; 362(17): 1605-17.
[http://dx.doi.org/10.1056/NEJMra0901557] [PMID: 20427809] 
[16] 
Wörmann SM, Algül H. Risk factors and therapeutic targets in pancreatic cancer. Front Oncol  2013; 3(282): 282.
[http://dx.doi.org/10.3389/fonc.2013.00282] [PMID: 24303367] 
[17] 
Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res  2009; 681(2-3): 299-307.
[http://dx.doi.org/10.1016/j.mrrev.2008.12.001] [PMID: 19150414] 
[18] 
Hsu C, Saif MW. Diabetes and pancreatic cancer: Highlights from the “ASCO annual meeting”. J Pancreas  2011; 12(4): 330-3.
[PMID: 21737889] 
[19] 
Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas  2004; 29(1): e1-8.
[http://dx.doi.org/10.1097/00006676-200407000-00061] [PMID: 15211117] 
[20] 
Qu X, Yao C, Wang J, Li Z, Zhang Z. Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin’s cell. Int J Nanomedicine  2012; 7: 6095-103.
[http://dx.doi.org/10.2147/IJN.S37212] [PMID: 23269868] 
[21] 
Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology  2009; 77(6): 400-10.
[http://dx.doi.org/10.1159/000279388] [PMID: 20130423] 
[22] 
Chellappan DK, Leng KH, Jia LJ, et al. The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. Biomed Pharmacother  2018; 102: 1127-44.
[http://dx.doi.org/10.1016/j.biopha.2018.03.061] [PMID: 29710531] 
[23] 
Baldo P, Giacomin E, Cecco S, D’Amico R, Cannizzaro R, Balduzzi S. Erlotinib for advanced pancreatic cancer. Cochrane Database Syst Rev  2015; 8: 1-12.
[24] 
Awasthi R, Roseblade A, Hansbro PM, Rathbone MJ, Dua K, Bebawy M. Nanoparticles in cancer treatment: Opportunities and obstacles. Curr Drug Targets  2018; 19(14): 1696-709.
[http://dx.doi.org/10.2174/1389450119666180326122831] [PMID: 29577855] 
[25] 
Awasthi R, Rathbone MJ, Hansbro PM, Bebawy M, Dua K. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology. Drug Deliv Transl Res  2018; 8(1): 97-110.
[http://dx.doi.org/10.1007/s13346-017-0440-1] [PMID: 29185148] 
[26] 
Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol  2009; 27(33): 5513-8.
[http://dx.doi.org/10.1200/JCO.2009.24.2446] [PMID: 19858379] 
[27] 
Ganjoo KN, Wakelee H. Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics  2007; 1(4): 335-46.
[PMID: 19707304] 
[28] 
Siddiqui F, Kachnic LA, Movsas B. Quality-of-life outcomes in oncology. Hematol Oncol Clin North Am  2006; 20(1): 165-85.
[http://dx.doi.org/10.1016/j.hoc.2006.01.003] [PMID: 16580562] 
[29] 
Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer  1997; 33(7): 1025-30.
[http://dx.doi.org/10.1016/S0959-8049(97)00049-X] [PMID: 9376182] 
[30] 
Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer  2002; 38(10): 1351-7.
[http://dx.doi.org/10.1016/S0959-8049(02)00098-9] [PMID: 12091066] 
[31] 
Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol  2008; 26(8): 1355-63.
[http://dx.doi.org/10.1200/JCO.2007.13.3439] [PMID: 18227528] 
[32] 
Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol  2009; 27(34): 5816-22.
[http://dx.doi.org/10.1200/JCO.2009.23.7420] [PMID: 19858383] 
[33] 
Schuette W, Tesch H, Büttner H, Krause T, Soldatenkova V, Stoffregen C. Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life. BMC Cancer  2012; 12: 14-20.
[http://dx.doi.org/10.1186/1471-2407-12-14] [PMID: 22244076] 
[34] 
Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manage  2002; 23(5): 417-23.
[http://dx.doi.org/10.1016/S0885-3924(02)00376-7] [PMID: 12007759] 
[35] 
Zabernigg A, Giesinger JM, Pall G, et al. Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC Cancer  2012; 12: 390-402.
[http://dx.doi.org/10.1186/1471-2407-12-390] [PMID: 22950826] 
[36] 
Timmers L, Boons CC, Moes-Ten Hove J, et al. Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol  2015; 141(8): 1481-91.
[http://dx.doi.org/10.1007/s00432-015-1935-0] [PMID: 25743274] 
[37] 
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med  2005; 353(2): 123-32.
[http://dx.doi.org/10.1056/NEJMoa050753] [PMID: 16014882] 
[38] 
Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol  2006; 24(24): 3831-7.
[http://dx.doi.org/10.1200/JCO.2006.05.8073] [PMID: 16921034] 
[39] 
Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). J Thorac Oncol  2012; 7(10): 1490-502.
[http://dx.doi.org/10.1097/JTO.0b013e318265b2b5] [PMID: 22982650] 
[40] 
Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer  2012; 13(2): 107-14.
[http://dx.doi.org/10.1016/j.cllc.2011.08.005] [PMID: 22056888] 
[41] 
Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol  2009; 27(36): 6251-66.
[http://dx.doi.org/10.1200/JCO.2009.23.5622] [PMID: 19917871] 
[42] 
Coudert B, Ciuleanu T, Park K, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol  2012; 23(2): 388-94.
[http://dx.doi.org/10.1093/annonc/mdr125] [PMID: 21610154] 
[43] 
Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist  2006; 11(6): 655-65.
[http://dx.doi.org/10.1634/theoncologist.11-6-655] [PMID: 16794244] 
[44] 
Vamvakas L, Agelaki S, Kentepozidis NK. Pemetrexed (MTA) compared with erlotinib (ERL) in pre-treated patients with advanced non-small-cell lung cancer (NSCLC): Results of a randomised phase III Hellenic Oncology Research Group trial. J Clin Oncol  2010; 28(15): 543-9.
[45] 
Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol  2004; 22(16): 3238-47.
[http://dx.doi.org/10.1200/JCO.2004.11.057] [PMID: 15310767] 
[46] 
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol  2007; 25(15): 1960-6.
[http://dx.doi.org/10.1200/JCO.2006.07.9525] [PMID: 17452677] 
[47] 
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol  1982; 5(6): 649-55.
[http://dx.doi.org/10.1097/00000421-198212000-00014] [PMID: 7165009] 
[48] 
Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol  2007; 25(18): 2607-15.
[http://dx.doi.org/10.1200/JCO.2006.09.2551] [PMID: 17577041] 
[49] 
EORTC Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30).  Available from: https://eprovide.mapi-trust.org/instruments/eortc-quality-of-life-questionnaire-core-questionnaire
[50] 
Quality of life in lung cancer – EORTC brings the measurements up to date.  Available from: https://www.eortc.org/blog/2020/03/24/qol-lung-cancer-update-protocol/
[51] 
Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev  2013; 3(1): 15.
[http://dx.doi.org/10.1186/2191-1991-3-15] [PMID: 23680096] 
[52] 
Psychometric Properties of the EORTC QLQ-LC29.  Available from: https://clinicaltrials.gov/ct2/show/NCT02745691
[53] 
Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol  1993; 11(3): 570-9.
[http://dx.doi.org/10.1200/JCO.1993.11.3.570] [PMID: 8445433] 
[54] 
Beér SA, Giboda M, Ditrich O. The differentiation of Opisthorchis eggs by the ultrastructure of their outer membranes. Med Parazitol (Mosk)  1990; (5): 48-51.
[PMID: 2266905] 
[55] 
EQ-VAS an important and under-used element of the EQ-5D.  Available from: https://www.ohe.org/news/eq-vas-important-and-under-used-element-eq-5d
[56] 
Kumar A, Mohan M. Acute naphthalene poisoning. Indian Pediatr  1986; 23(Suppl.): 175-6.
[PMID: 3666900] 
[57] 
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.  Available from: https://clinicaltrials.gov/
[58] 
AZD9291 versus gefitinib or erlotinib in patients with locally advanced or metastatic non-small cell lung cancer (FLAURA).  Available from: https://ClinicalTrials.gov/show/NCT02296125
[59] 
LUX-Lung 8: A phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy.  Available from: https://ClinicalTrials.gov/show/NCT01523587
[60] 
Efficacy trial comparing ZD6474 with erlotinib in NSCLC after failure of at least one prior chemotherapy.  Available from: https://ClinicalTrials.gov/show/NCT00364351
[61] 
Ph II gemcitabine, erlotinib, and gemcitabine with erlotinib/elderly patients W/IIIB/IV NSCLC.  Available from: https://ClinicalTrials.gov/show/NCT00283244
[62] 
ARCHER 1009 : a study of dacomitinib (PF-00299804) Vs. erlotinib in the treatment of advanced non-small cell lung cancer (ARCHER 1009).  Available from: https://ClinicalTrials.gov/show/NCT01360554
[63] 
A study of erlotinib in locally advanced, unresectable, or metastatic pancreatic cancer.  Available from: https://ClinicalTrials.gov/show/NCT02694536
[64] 
A study to assess the incidence of egfr mutation in patients with newly diagnosed locally advanced or metastatic non-small cell lung cancer in the UK, and of tarceva (erlotinib) as first-line therapy in egfr mutation positive patients.  Available from: https://ClinicalTrials.gov/show/NCT01250119
[65] 
A study of tarceva (erlotinib) in elderly patients with advanced non-small cell lung cancer.  Available from: https://ClinicalTrials.gov/show/NCT01196078
[66] 
A study of management of tarceva - induced rash in patients with non-small cell lung cancer.  Available from: https://ClinicalTrials.gov/show/NCT00531934
[67] 
A randomized trial of PF-00299804 taken orally versus erlotinib taken orally for treatment of advanced non-small cell lung cancer that has progressed after one or two prior chemotherapy regimen.  Available from: https://ClinicalTrials.gov/show/NCT00769067
[68] 
A study of tarceva (erlotinib) and standard of care chemotherapy in patients with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).  Available from: https://ClinicalTrials.gov/show/NCT00556322
[69] 
Erlotinib is being studied with or without an investigational drug, pf-02341066, in patients with lung cancer.  Available from: https://ClinicalTrials.gov/show/NCT00965731
[70] 
A study of tarceva (erlotinib) or placebo in combination with platinum-based therapy as first line treatment in patients with advanced or recurrent non-small cell lung cancer.  Available from: https://ClinicalTrials.gov/show/NCT00883779
[71] 
A study of erlotinib (tarceva) versus gemcitabine/cisplatin as first-line treatment in patients with non-small cell lung cancer with EGFR mutations.  Available from: https://ClinicalTrials.gov/show/NCT01342965
[72] 
A study of tarceva (erlotinib) following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).  Available from: https://ClinicalTrials.gov/show/NCT00556712
[73] 
A study in patients with non-small cell lung cancer to test if erlotinib plus su011248 is better than erlotinib alone.  Available from: https://ClinicalTrials.gov/show/NCT00457392
[74] 
A feasibility study of chinese herbs to manage cancer-related symptoms in patients with advanced NSCLC (CH).  Available from: https://ClinicalTrials.gov/show/NCT02331394
[75] 
A study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL).  Available from: https://ClinicalTrials.gov/show/NCT00532155
[76] 
A study of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer (ESSENCE).  Available from: https://ClinicalTrials.gov/show/NCT01667562
[77] 
A clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with ALK positive non squamous cancer of the lung (PROFILE 1014).  Available from: https://ClinicalTrials.gov/show/NCT01154140
[78] 
A 3rd/4th line placebo-controlled trial of sorafenib in patients with predominantly non squamous non-small cell lung cancer (NSCLC). (MISSION).  Available from: https://ClinicalTrials.gov/show/NCT00863746
[79] 
A study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy (OAK).  Available from: https://ClinicalTrials.gov/show/NCT02008227
[80] 
Study of cisplatin/vinorelbine +/- cetuximab as first-line treatment of advanced non small cell lung cancer (FLEX) (FLEX).  Available from: https://ClinicalTrials.gov/show/NCT00148798
[81] 
A phase III randomized, double-blind, placebo controlled trial comparing the efficacy of gemcitabine, cisplatin and sorafenib to gemcitabine, cisplatin and placebo in first-line treatment of patients with stage iiib with effusion and stage iv non-small cell lung cancer (NSCLC) (NEXUS).  Available from: https://ClinicalTrials.gov/show/NCT00449033
[82] 
A study in patients with non-small cell lung cancer testing if erlotinib plus su011248 (sunitinib) is better than erlotinib alone (SUN1058).  Available from: https://ClinicalTrials.gov/show/NCT00265317
[83] 
SELINE: second-line iressa phase IV study in NSCLC patients (SELINE).  Available from: https://ClinicalTrials.gov/show/NCT00608868
[84] 
A study of emibetuzumab in non small cell lung cancer (NSCLC) participants (Chime).  Available from: https://ClinicalTrials.gov/show/NCT01900652

Rights & Permissions Print Cite

Article Metrics

16

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/2212697X07999200820162006	Print ISSN 2212-697X
Publisher Name Bentham Science Publisher	Online ISSN 2212-6988

Clinical Cancer Drugs

Role of Erlotinib in Influencing the Quality of Life of Cancer Patients

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract